How Does Bulevirtide Work? Mechanism of Action, Per the Research

Bulevirtide is a prescription medicine, not a supplement or a consumer product. It is described in the pharmacology literature as a first-in-class hepatitis B and hepatitis D virus entry inhibitor (PMID 34268531). Any application outside an approved indication is investigational. This page summarises what published studies and reviews report about the molecular target and downstream physiology. This page is for educational purposes only and is not medical advice; consult a licensed physician or prescribing clinician about any medicine, including whether it is appropriate for a given person.

What Bulevirtide Is at the Molecular Level

Bulevirtide is a synthetic lipopeptide corresponding to the N-terminal preS1 domain of the hepatitis B virus large surface protein, carrying a myristoyl group on its N-terminus, as described in a pharmacology review of the compound (PMID 34268531). That same review reported that the peptide was designed to imitate the part of the viral envelope that docks onto hepatocytes, so that it competes with the virus for the same binding site (PMID 34268531).

Reviews of chronic hepatitis delta management described bulevirtide as having received conditional marketing authorisation in the European Union for chronic hepatitis delta virus infection in adults with compensated liver disease (PMID 36428959). Approved labelling defines who may be considered for treatment and under what monitoring; that determination is a prescriber's, not a reader's. Dosing, preparation and administration are label and clinician territory and are deliberately not covered here.

The Receptor Target: NTCP (SLC10A1)

The established molecular target is the sodium taurocholate cotransporting polypeptide, abbreviated NTCP and encoded by SLC10A1. A 2024 review of NTCP biology reported that the protein sits on the basolateral (sinusoidal) membrane of hepatocytes, where its normal physiological job is sodium-dependent uptake of conjugated bile salts returning from the portal circulation, and that it also serves as the functional receptor for hepatitis B virus (PMID 39494152). That dual identity, transporter and viral receptor, is the whole basis of the drug's mechanism.

Because NTCP is expressed almost exclusively on differentiated hepatocytes, the review noted that receptor distribution helps explain the strict liver tropism of hepatitis B infection (PMID 39494152). A peptide that occupies the receptor therefore acts mainly where the receptor is, which is the liver.

Why Hepatitis D Uses the Same Door

Hepatitis delta virus is a satellite agent: it encodes its own ribonucleoprotein but borrows the hepatitis B surface antigen envelope to form infectious particles, as outlined in a virology review of HDV (PMID 36396025). Structural work published in 2026 characterised the HDV virion and its ribonucleoprotein core, reinforcing that the outer coat of the particle is supplied by hepatitis B surface proteins (PMID 41564123). Since the delta particle wears a hepatitis B envelope, it binds hepatocytes through the same preS1 to NTCP interaction, which is why a preS1-derived blocker is relevant to both viruses (PMID 36396025).

Established Mechanism: Receptor Occupancy and Entry Blockade

The mechanism with the strongest support is competitive blockade of virus attachment. A pharmacology review reported that bulevirtide binds NTCP with high affinity and prevents hepatitis B and hepatitis D virions from engaging the receptor, thereby inhibiting entry into hepatocytes (PMID 34268531). Reviews of hepatitis delta treatment described the consequence at the tissue level: new infection events are interrupted, so the virus cannot propagate into previously uninfected liver cells (PMID 36428959).

Two points follow from that logic and are stated explicitly in the review literature. First, an entry inhibitor acts on the spread of infection rather than on intracellular replication machinery already present inside an infected cell (PMID 36428959). Second, because hepatitis delta depends on a continuing supply of hepatitis B surface antigen, reviews of emerging hepatitis D therapy discussed entry inhibition alongside strategies aimed at surface antigen production and at the delta ribonucleoprotein itself (PMID 40606936).

Structural Evidence for the Binding Mode

A 2024 structural study resolved bulevirtide bound to human NTCP and reported that the myristoylated N-terminal segment of the peptide inserts into the transporter, occupying the region used for bile acid translocation and locking the protein in a conformation that is unavailable to the virus (PMID 38509088). The study therefore provided a physical explanation for two observations at once: blocked viral attachment and interference with the transporter's native substrate handling (PMID 38509088). A complementary review of NTCP summarised how the receptor binding surface and the bile salt pathway overlap (PMID 39494152).

Laboratory Breadth Across Viral Genotypes (In Vitro Work)

A 2023 in vitro study tested bulevirtide against clinical isolates of hepatitis delta virus and against recombinant pan-genotypic hepatitis B and hepatitis D combinations, and researchers reported broad-spectrum inhibitory activity across the genotype panel examined in cell culture (PMID 37929228). That work was laboratory work, performed in cell systems rather than in people, and the study framed it as characterisation of antiviral spectrum rather than as a clinical outcome (PMID 37929228).

Downstream Physiology: What Happens to Bile Salt Transport

Because the drug target is a bile acid transporter, the same binding event that blocks the virus also affects the transporter's day job. A 2025 clinical pharmacology review reported that NTCP inhibition by bulevirtide is associated with increases in circulating bile salts, and discussed how that transporter engagement shapes known and potential drug-drug interaction considerations, including with medicines handled by hepatic uptake transporters (PMID 40006617). The structural study offered the mechanistic counterpart, showing peptide occupancy of the substrate pathway (PMID 38509088). Interaction screening and monitoring decisions belong to a prescribing clinician who can see the full medication list.

Established Versus Proposed Mechanism

Proposed Mechanistic Extensions

Several ideas sit beyond the settled entry-blockade story. Reviews of interferon-free and combination approaches to delta hepatitis discussed pairing entry inhibition with immunomodulatory or direct-acting agents, on the reasoning that different stages of the viral life cycle are addressed by different classes, and described those combinations as an active research question rather than a closed one (PMID 37886941). A review of alternatives and adjuncts to bulevirtide catalogued other mechanistic targets under investigation for hepatitis delta, including prenylation inhibition and nucleic acid polymers, which act at steps the entry inhibitor does not touch (PMID 36529713). A 2025 review of emerging hepatitis D therapies placed entry inhibition within that wider pipeline (PMID 40606936).

On liver disease trajectory, a literature review of hepatitis B and D virus infection and hepatocellular carcinoma discussed the diagnostic, therapeutic and prognostic landscape for coinfected patients, which is the context in which long-term questions about antiviral therapy are framed (PMID 39454228). Mechanism and long-term outcome are separate questions, and the literature treats them separately.

What the Mechanism Does Not Explain

Blocking the receptor does not act on viral genetic material already established inside hepatocytes, a limitation that reviews of hepatitis delta treatment discussed when explaining why response and relapse patterns are followed over long horizons (PMID 36428959). Virology reviews also noted that the delta ribonucleoprotein replicates using host enzymes, which is a step an entry inhibitor does not reach (PMID 36396025). Structural characterisation of the virion and its ribonucleoprotein was presented as groundwork for targeting those other steps (PMID 41564123).

Bulevirtide Adverse Events: What Studies Report

Reviews of the clinical development programme reported injection site reactions and increases in bile salt levels among the findings observed in treated participants, with the bile salt signal linked mechanistically to inhibition of the NTCP transporter rather than to an off-target effect (PMID 36428959). A 2025 clinical pharmacology review likewise reported bile salt elevation as a pharmacologically expected consequence of NTCP engagement and examined its implications for interactions with co-administered medicines (PMID 40006617). An earlier pharmacology review summarised the tolerability profile described across the compound's development (PMID 34268531). Monitoring, interpretation of laboratory changes and any decision about continuing or stopping a medicine are matters for a prescribing clinician.

Questions a Prescriber Can Answer

• Whether an approved indication applies to a specific clinical situation, and what the label states.
• How other prescribed medicines might interact with a drug that engages a hepatic uptake transporter (PMID 40006617).
• What laboratory monitoring is appropriate during treatment, and how bile salt changes are interpreted (PMID 36428959).
• How entry inhibition fits alongside other hepatitis delta strategies still under investigation (PMID 40606936).

Talk to a prescriber about any of these. Nothing on this page is a recommendation to use, start, continue or stop any medicine.

References

• Bulevirtide for HBV and HDV infections (Drugs of Today, 2021)
• Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP (Nature Communications, 2024)
• The Culprit Behind HBV-Infected Hepatocytes: NTCP (Drug Design, Development and Therapy, 2024)
• Treatment of Chronic Hepatitis D with Bulevirtide, A Fight against Two Foes, An Update (Cells, 2022)
• Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV (JHEP Reports, 2023)
• Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug-Drug Interactions (Pharmaceutics, 2025)
• Hepatitis D virus: Improving virological knowledge to develop new treatments (Antiviral Research, 2023)
• Structural characterization of the HDV virion and its ribonucleoprotein (PNAS, 2026)
• Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet? (Current Issues in Molecular Biology, 2023)
• Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus (Journal of Viral Hepatitis, 2023)
• Hope on the horizon: Emerging therapies for hepatitis D (World Journal of Hepatology, 2025)
• Epidemiological, diagnostic, therapeutic and prognostic impact of hepatitis B and D virus infection on hepatocellular carcinoma: A review of the literature (Virology, 2024)